HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression

Hu, Xiaosi; Pan, Hongtao; Zhou, Shuai; Pang, Qing; Wang, Yong; Chen, Zhu; Liu, Huichun; Hao, Jian; Xu, Aman

doi:10.1016/j.bbrc.2022.07.047

Cited by 8 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[24][25][26] According to Hu X, the fusion of estrogen receptor 1 (ESR1) with the HS1BP3 promoter was discovered to have the ability to hinder HCC proliferation and enhance prognosis. [27] Sun Z found that the mouse TSG101 gene, or a segment of it, hinders ligand-induced activation of nuclear receptors like AR and ESR, crucial for prostate and breast cancer. [28] Moreover, Yang C noted that AR diminishes the functionality and aridity of male tumor-infiltrating CD8 + T cells through modification of epigenetic and transcriptional pathways.…”

Section: Discussionmentioning

confidence: 99%

Explore the mechanism of Astragalus membranaceus and Poria cocos drug pair in improving immunity based on network pharmacology

Bai,

Ning,

Zhao

et al. 2024

Medicine

View full text Add to dashboard Cite

The aim of this study was to investigate the key targets and molecular mechanisms of the drug pair Astragalus membranaceus and Poria cocos (HFDP) in the treatment of immunity. We utilized network pharmacology, molecular docking, and immune infiltration techniques in conjunction with data from the GEO database. Previous clinical studies have shown that HFDP has a positive impact on immune function. We first identified the active ingredients and targets of HFDP from the Traditional Chinese Medicine Systems Pharmacology database and the Swiss Target Prediction database, respectively. Next, we retrieved the differentially expressed genes (DEGs) related to immunity from the GEO databases. The intersection targets of the drugs and diseases were then analyzed using the STRING database for protein-protein interaction (PPI) network analysis, and the core targets were determined through topological analysis. Finally, the intersection genes were further analyzed using the DAVID database for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes analyses. Subsequently, by analyzing the expression and prognostic survival of 12 core targets, 5 core target genes were identified, and molecular docking between the hub genes and immunity was performed. Finally, we used the CIBERSORT algorithm to analyze the immune infiltration of immunity genes In this study, 34 effective ingredients of HFDP, 530 target genes, and 568 differential genes were identified. GO and KEGG analysis showed that the intersection genes of HFDP targets and immunity-related genes were mainly related to complement and coagulation cascades, cytokine receptors, and retinol metabolism pathways. The molecular docking results showed that the 5 core genes had obvious affinity for the active ingredients of HFDP, which could be used as potential targets to improve the immunity of HFDP. Our findings suggest that HFDP is characterized by “multiple components, multiple targets, and multiple pathways” in regulating immunity. It may play an essential role in regulating immunity by regulating the expression and polymorphism of the central target genes ESR1, JUN, CYP3A4, CYP2C9, and SERPINE1.

show abstract

Section: Discussionmentioning

confidence: 99%

Explore the mechanism of Astragalus membranaceus and Poria cocos drug pair in improving immunity based on network pharmacology

Bai,

Ning,

Zhao

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Zhang et al, found that ESR1 could inhibit the occurrence and development of HCC by regulating the gene MMAA, an obesity and metabolism differential gene [31]. In addition, Hu et al, revealed that ESR1 also could promote HCC progression via transcriptionally regulating HS1BP3 [32]. These evidences all suggested that ESR1 was a potential therapeutic target in HCC.…”

Section: Discussionmentioning

confidence: 99%

RNA methylation patterns mediated by m 6 A regulators are involved in the regulation of immune microenvironment in hepatocellular carcinoma

Gao

Liu

Zhang

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: It has been reported that epigenetic regulation is emerging as a new regulatory pattern, especially for RNA N6-methyladenosine (m6A) modifications. It has been reported to play an important biological function in immunity. However, the role of m6A on the immune microenvironment in hepatocellular carcinoma (HCC) remains unclear. In this study, we systematically evaluated the RNA modification patterns mediated by 23 m6A modulators in HCC samples using the TCGA database. Methods and results: The effects of m6A modification on the characteristics of immune microenvironment gene were investigated. Meanwhile, we characterized m6A phenotype-related immune genes. Our study further identified two distinct patterns of RNA modification mediated by 23 m6A modulators. They have different immune cell abundances, immune responses, and HLA genes. Conclusion: In a word, our findings suggest that m6A modification plays a crucial role in regulating the immune microenvironment in HCC, providing a guiding significance in the selection of immunotherapy or target for treating HCC.

show abstract

“…The refined network allowed us to isolate two hub regulatory networks: Networks centered on the first strategy (CBX2/CEP55/MCM2) and the second strategy (ESR1) (Figure 1E and Supplementary Figure 2A). Through experimentation, it had been demonstrated that ESR1 prevented the growth and metastasis of HCC [18]. Tumor cell migration and proliferation were facilitated by DUXAP8, CDKN2B-AS1, and MCM3AP-AS1 in HCC [8][9][10].…”

Section: Cbx2/cep55-center Hub-refined Regulatory Networkmentioning

confidence: 99%

Prognostic hub gene CBX2 drives a cancer stem cell-like phenotype in HCC revealed by multi-omics and multi-cohorts

Meng,

Zhou,

Chen

et al. 2023

Aging

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a malignant tumor with a high prevalence and fatality rate. CBX2 has been demonstrated to impact the development and advancement of various cancers, albeit it has received limited attention in relation to HCC. In this study, CBX2 and CEP55 were screened out with the refined triple regulatory networks constructed by total RNA-seq datasets (TCGA-LIHC, GSE140845) and a robust prognostic model. Aberrantly higher expression levels of CBX2 and CEP55 in HCC may be caused by CNV alterations, promoter hypo-methylation, open chromatin accessibility, and greater active marks such as H3K4me3, H3K4me1, and H3K27ac. Functionally, CBX2 , which was highly correlated with CD44, shaped a cancer stem cell-like phenotype by positively regulating cell-cycle progression, proliferation, invasion, metastasis, wound healing, and radiation resistance, revealed by combining bulk RNA-seq and scRNA-seq datasets. CBX2 knockdown validated its role in affecting the cell cycle. Importantly, we revealed CBX2 could activate gene by cooperating with co-regulators or not rather than a recognizer of the repressive mark H3K27me3. For instance, we uncovered CBX2 bound to promoter of CTNNB1 and CEP55 to augment their expressions. CBX2 showed a highly positive correlation with CEP55 at pan-cancer level. In addition, CBX2 and CEP55 may enhance extracellular matrix reprograming via cancer-associated fibroblast. Surprisingly, patients with high expression of CBX2 or CEP55 exhibited a higher response to immunotherapy, indicating that CBX2 and CEP55 may be promising therapeutic targets for HCC patients.

show abstract

HS1BP3, transcriptionally regulated by ESR1, promotes hepatocellular carcinoma progression

Cited by 8 publications

References 23 publications

Explore the mechanism of Astragalus membranaceus and Poria cocos drug pair in improving immunity based on network pharmacology

Explore the mechanism of Astragalus membranaceus and Poria cocos drug pair in improving immunity based on network pharmacology

RNA methylation patterns mediated by m 6 A regulators are involved in the regulation of immune microenvironment in hepatocellular carcinoma

Prognostic hub gene CBX2 drives a cancer stem cell-like phenotype in HCC revealed by multi-omics and multi-cohorts

Contact Info

Product

Resources

About